Zepbound FAQ: The Questions People Ask Google

Zepbound is now the most prescribed injectable weight-management medicine in the United States, and the questions people bring to search engines reflect that: not “what is it” so much as “which dose is a real maintenance dose,” “why did the warning change,” and “why does my new box say 30 days when my last one said 21.”

Here are the answers, taken from the current FDA label and Eli Lilly’s own published pricing and support material. Nothing here is medical advice, and nothing here tells you what dose to take or whether to take Zepbound at all. Those belong with a healthcare provider.

What is Zepbound used for?

The label lists two indications, both in combination with a reduced-calorie diet and increased physical activity [1]:

1. To reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition
2. To treat moderate-to-severe obstructive sleep apnea in adults with obesity

The second one, approved December 20, 2024, made Zepbound the first prescription medicine ever approved for obstructive sleep apnea [2].

There is also a limitation of use that applies to both: Zepbound contains tirzepatide, and taking it alongside another tirzepatide product or any GLP-1 receptor agonist is not recommended [1].

Is Zepbound the same as Mounjaro?

Same active ingredient — tirzepatide — same manufacturer, same once-weekly injection, same six strengths. Different approved uses. Mounjaro is for type 2 diabetes and, since August 2026, for reducing cardiovascular risk in adults with type 2 diabetes. Zepbound is the brand approved for weight management and sleep apnea [1].

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is what separates it from semaglutide (Ozempic, Wegovy), a GLP-1 receptor agonist alone.

What doses does Zepbound come in, and which are maintenance doses?

Six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg [1].

The escalation, as the label describes it: 2.5 mg once weekly for four weeks, then 5 mg once weekly, then increases of 2.5 mg after at least four weeks on the current dose [1].

Where people get tripped up is the difference between a strength and a maintenance dose. The label is explicit [1]:

• 2.5 mg is for treatment initiation and is not approved as a maintenance dosage. It exists to reduce gastrointestinal side effects during the first month.
• For weight reduction and long-term maintenance, the recommended maintenance dosage is 5 mg, 10 mg or 15 mg.
• For obstructive sleep apnea, the recommended maintenance dosage is 10 mg or 15 mg.
• The maximum for all indications is 15 mg once weekly.

That leaves 7.5 mg and 12.5 mg as step-up rungs rather than named destinations. The label does add that prescribers should consider treatment response and tolerability when selecting a maintenance dosage, and that if a patient does not tolerate one, a lower maintenance dosage may be considered [1].

Missed doses: the label says to take it as soon as possible within four days (96 hours), and if more than four days have passed, skip it and resume the regular schedule. The injection day can be changed as long as at least three days (72 hours) separate the two doses [1].

How much weight did people lose in the trials?

Two 72-week placebo-controlled trials support the weight-management indication. From the label’s Table 2 [1]:

Study 1 — adults with obesity or overweight, without type 2 diabetes:

	Placebo	5 mg	10 mg	15 mg
Average weight change	-3.1%	-15.0%	-19.5%	-20.9%
Lost at least 5%	34.5%	85.1%	88.9%	90.9%
Lost at least 10%	18.8%	68.5%	78.1%	83.5%
Lost at least 15%	8.8%	48.0%	66.6%	70.6%
Lost at least 20%	3.1%	30.0%	50.1%	56.7%

Study 2 — adults who also had type 2 diabetes:

	Placebo	10 mg	15 mg
Average weight change	-3.2%	-12.8%	-14.7%
Lost at least 5%	32.5%	79.2%	82.8%

Average starting weight was around 105 kg (about 231 pounds) in Study 1 [1].

A third trial, Study 4, tested what happens when treatment stops. After 36 weeks of open-label Zepbound, participants were re-randomized. Between week 36 and week 88, the group switched to placebo gained 14.0 percent of body weight back, while the group who stayed on Zepbound lost a further 5.5 percent [1]. That is the clearest label evidence that Zepbound is framed as long-term maintenance, not a course of treatment.

The label also records improvements alongside weight: waist circumference, systolic and diastolic blood pressure, triglycerides, non-HDL cholesterol and HbA1c all moved more on Zepbound than on placebo [1].

What are the most common side effects?

From the pooled Studies 1 and 2, adverse reactions occurring in at least 2 percent of Zepbound-treated patients and more often than placebo [1]:

	Placebo	5 mg	10 mg	15 mg
Nausea	8%	25%	29%	28%
Diarrhea	8%	19%	21%	23%
Vomiting	2%	8%	11%	13%
Constipation	5%	17%	14%	11%
Abdominal pain	5%	9%	9%	10%
Indigestion	4%	9%	9%	10%
Injection site reactions	2%	6%	8%	8%
Fatigue	3%	5%	6%	7%
Hair loss	1%	5%	4%	5%

Gastrointestinal reactions of any kind occurred in about 56 percent of Zepbound-treated patients at every dose, versus 30 percent on placebo. The label notes that most nausea, vomiting and diarrhea happened during dose escalation and decreased over time [1].

What warnings does Zepbound carry?

A boxed warning about thyroid C-cell tumors: in rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. Whether it does so in humans is unknown, because the human relevance of the rodent finding has not been determined [1].

Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, and anyone with a known serious hypersensitivity to tirzepatide or an ingredient [1].

The other warnings, in the label’s numbering [1]: severe gastrointestinal adverse reactions (5.2, and Zepbound is not recommended in people with severe gastroparesis), acute kidney injury due to volume depletion (5.3), acute gallbladder disease (5.4), acute pancreatitis (5.5), hypersensitivity reactions (5.6), hypoglycemia (5.7), diabetic retinopathy complications in people with type 2 diabetes (5.8), pulmonary aspiration during general anesthesia or deep sedation (5.9), and never share a Zepbound KwikPen between patients (5.10).

Two more things the label asks patients to know: oral birth control pills may work less well, so the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase; and there is a pregnancy exposure registry for women who take Zepbound during pregnancy, with the contact details in the Medication Guide [1].

Why did the suicidality warning disappear?

Because FDA asked for it to go.

FDA had been evaluating a possible signal for suicidal ideation across the GLP-1 class since July 2023. On January 13, 2026, it issued a supplement request letter asking Lilly to remove the information from the Zepbound label. The change was folded into an existing review and approved on February 25, 2026 [3].

That supplement removed subsection 5.9, Suicidal Ideation and Behavior, from Warnings and Precautions and struck “depression or thoughts of suicide” from the Medication Guide’s side effect list [3].

The same supplement went the other direction on a different issue. Following an April 2025 notification of a newly identified safety signal for intestinal obstruction and fecal impaction across the GLP-1 class, FDA required two additions: a line in the severe gastrointestinal reactions warning noting that severe GI reactions have also been reported postmarketing with GLP-1 receptor agonists, and the addition of “intestinal obstruction, severe constipation including fecal impaction” to the Postmarketing Experience section [3].

What devices does Zepbound come in?

Four [1]:

• Single-dose pen, four per carton, needle built in. The presentation used in every Phase 3 trial.
• Single-dose vial, in 1-packs and 4-packs. Needs a needle and syringe you buy separately.
• Multi-dose vial, four 0.6 mL doses per 2.4 mL vial, approved January 7, 2026.
• Single-patient-use KwikPen, four weekly doses per pen, approved January 20, 2026 and launched February 23, 2026 [4][5].

Single-dose pens and vials are preservative-free and deliver 0.5 mL per dose. Multi-dose vials and KwikPens use a preserved formulation containing phenol and benzyl alcohol, plus glycerin, and deliver 0.6 mL per dose. That is why the storage rules differ.

Can you share a KwikPen?

No, and this became a formal label warning in January 2026. Section 5.10 says never to share a Zepbound KwikPen between patients, even if the pen needle is changed, because sharing poses a risk for transmission of blood-borne pathogens [1]. The same warning appears in bold at the very top of the Medication Guide in the box.

The label also states that the KwikPen is not recommended for self-administration by people who are visually impaired, unless a healthcare provider determines they can administer it properly [1].

What are the storage rules?

They depend on the device, and the two sets of numbers are different [1]:

Single-dose pen or vial. Refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Each one may be kept unrefrigerated at no more than 30 degrees C (86 degrees F) for up to a total of 21 days, then must be discarded.

Multi-dose vial or KwikPen, unopened. Refrigerated, use until the expiration date. At room temperature, throw away after 30 days.

Multi-dose vial or KwikPen, in use. Store in the original carton in the refrigerator or at room temperature. Throw away after a total of 30 days at room temperature, 30 days after first use, or four weekly doses — whichever comes first — even if medicine remains.

Universal rules: do not freeze, do not use if frozen, protect from heat and light, keep in the original carton, and check that the liquid is clear and colorless to slightly yellow before injecting.

If you finish a KwikPen and see liquid still inside, that is normal. Lilly says the residual volume is there so the pen works correctly, the pen blocks a fifth full dose, and you should not inject the leftover or transfer it to a syringe.

What does Zepbound cost?

Three routes, three answers.

List price. Lilly publishes Zepbound’s wholesale acquisition cost as a range, $499 to $1,086.37 per fill, using AnalySource data as of January 1, 2026 (verified 2026-09-14) [6]. It is a range rather than a point figure, and Lilly does not break it down by presentation. Very few people pay list price.

Self-pay through LillyDirect. Per 28-day month of four single-dose vials or one KwikPen [7][8]:

Dose	With 45-day refill	Regular price
2.5 mg	$299	$299
5 mg	$399	$399
7.5 mg	$449	$499
10 mg	$449	$699
12.5 mg	$449	$699
15 mg	$449	$699

The refill condition is the Zepbound Self Pay Journey Program: to hold the $449 price on the top four doses, each refill must be purchased within 45 days of the delivery or receipt date of the previous prescription [8]. Needles and syringes are extra. Lilly’s December 2025 announcement put the regular prices at $599 for 7.5 mg, $849 for 12.5 mg and $1,049 for 15 mg [13]; the figures above are the ones Lilly publishes today and supersede them.

With commercial insurance. The Zepbound savings card can bring eligible patients whose plan covers the single-dose pen to as little as $25 for a one-, two- or three-month fill — capped at $100, $200 or $300 in savings per fill and $1,300 a year, for up to 13 fills, expiring December 31, 2026. If your commercial plan does not cover the pen, the card sets the price at as low as $499 a month. A separate set of terms applies to the KwikPen for commercially insured patients whose plan does not cover it, at $299 to $449 depending on strength [8]. The two cards carry different limits, and Lilly’s own terms state both: the single-dose pen card allows up to 13 prescription fills per calendar year, while the KwikPen card allows up to 11, with per-strength maximum savings of $215 at 2.5 mg, $115 at 5 mg, $65 at 7.5 mg and $271 at 10, 12.5 and 15 mg [8]. These are savings-card tiers, not self-pay prices, and every one of them is capped, so read the card terms before relying on the headline number.

Cash at a retail pharmacy. Since March 16, 2026, the KwikPen Self-Pay Savings Card has carried LillyDirect’s prices to major pharmacies nationwide. It is open to anyone paying cash, including uninsured patients, but it applies only to the KwikPen — not to vials and not to the single-dose pen [8].

Medicare. The Medicare GLP-1 Bridge program, a time-limited CMS demonstration running July 1, 2026 through December 31, 2027, lets eligible Medicare Part D enrollees pay no more than $50 a month for certain weight-management GLP-1 medicines. For Zepbound it covers the KwikPen only — CMS states that the single-dose Zepbound pen and Zepbound vials are not covered — and eligibility runs through your Part D plan, BMI criteria and a prior authorization [12].

Can children take Zepbound?

The label states it is not known whether Zepbound is safe and effective for use in children [1]. There is no pediatric indication.

Mounjaro, the same molecule under the other brand name, does have one: patients 10 years and older with type 2 diabetes, approved December 19, 2025, with a maximum dose of 10 mg.

Is Zepbound really the most prescribed weight-management medicine?

Lilly says so, and cites IQVIA National Prescription Audit data for total US prescriptions. In February 2026 the company described Zepbound as the number one prescribed injectable obesity-management medication and said one in three new patients starting a branded weight-management medicine in 2025 was prescribed Zepbound self-pay vials [5]. Treat those as manufacturer claims backed by a named prescription database rather than independent market research.

How do I check that my Zepbound is genuine?

Lilly runs a free tool at scan.lilly.com. Scan the 2D barcode printed on the outside of the carton — not the pen or vial, which cannot be scanned — and the site checks whether the serial number matches medicine made by Lilly and obtained in the United States [10].

Is there an app?

Yes, the free Lilly Health app. It stores savings card information, tracks doses, visualizes progress and syncs with smart devices and other health apps. Lilly notes that it is not intended to provide treatment decisions or replace a healthcare provider. There are also text-based starter kits: “ZB” to 85099 for weight management and “ZO” to 85099 for sleep apnea, plus how-to-use videos for all three devices [11].

Sources

1. ZEPBOUND (tirzepatide) injection and ZEPBOUND KWIKPEN — US Prescribing Information, revised 8/2026 (DailyMed)
2. Drugs@FDA: NDA 217806 (Zepbound) approval history
3. FDA supplement approval letter, NDA 217806/S-042 (Zepbound labeling), February 25, 2026
4. FDA supplement approval letter, NDA 217806/S-002 (Zepbound KwikPen), January 20, 2026
5. Zepbound, the most prescribed weight management medication in 2025, now available in multi-dose KwikPen — Eli Lilly, February 23, 2026
6. Zepbound Cost Information — Eli Lilly pricing site
7. Authentic Zepbound (tirzepatide) Shipped to You — LillyDirect
8. Zepbound (tirzepatide): Full Terms and Conditions — Eli Lilly
9. Savings and Insurance Options — Zepbound (tirzepatide)
10. Check the Authenticity of Your Zepbound and Mounjaro Medication — scan.lilly.com
11. Resources, Support, Tips and Guides — Zepbound (tirzepatide)
12. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234, June 2026)
13. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials — Eli Lilly, December 1, 2025